COVID-19 and antimicrobial therapy

BACKGROUND: One of the problems with managing patients a new coronavirus infection is irrational use antibiotics. Antibacterial drugs are not active against viral infection, including COVID-19. Unfortunately, in actual clinical practice, level antibiotic remains extremely high, reaching 7080%. Unwanted antibacterial therapy leads to number undesirable phenomena that can significantly worsen condition, and sometimes lead life-threatening consequences. In this context, most important question formulation diagnosis. particular, reference term pneumonia, case COVID-19, neither scientifically or clinically feasible. The correct would be call process virus-associated lung damage. This will allow you set priorities choice tactics leading patient. That is, lesion (not pneumonia!) induce practical doctor analyze situation requiring prescription presence indications anti-inflammatory (monoclonal antibodies, glucocorticosteroids) anticoagulation therapy, avoid unnecessary overwhelming antimicrobial situations.
 AIM: Formulate criteria for prescribing COVID-19.
 MATERIALS AND METHODS: study based on review analysis literature drawing conclusions recommendations.
 RESULTS: Russian antibiotics 7080%.
 CONCLUSION: COVID-19 justified only if there convincing signs bacterial appearance purulent sputum, increased procalcitonin blood more than 0,250.5 ng/ml, an increase white count 10 thousand/mcl band neutrophils 10%.